Serum levels of VEGF-A, sVEGFR-2 and galectin-3 do not correlate with clinical stage, tumor size, or effectiveness of perioperative chemotherapy in patients with non-metastatic breast cancer

Serum levels of VEGF-A, sVEGFR-2 and galectin-3 do not correlate with clinical stage, tumor size, or effectiveness of perioperative chemotherapy in patients with non-metastatic breast cancer

Introduction Tumor angiogenesis is regulated by numerous cytokines and growth factors, with vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 2 (sVEGFR-2), and galectin-3, playing a significant role in the process. There are conflicting data concerning ch...

Full description

Bibliographic Details
Main Authors: Iga Grochoła-Małecka, Paulina Czajka-Francuz, Aleksander Jerzy Owczarek, Jerzy Wojnar, Gabriela Handzlik, Tomasz Francuz, Jerzy Chudek
Format: Article
Language:English
Published: Śląski Uniwersytet Medyczny w Katowicach 2022-09-01
Series:Annales Academiae Medicae Silesiensis
Subjects:
breast cancer
angiogenesis
galectin-3
vascular endothelial growth factor
chemotherapy
Online Access:https://annales.sum.edu.pl/Serum-levels-of-VEGF-A-sVEGFR-2-and-galectin-3-do-not-correlate-with-clinical-stage,149208,0,2.html

Internet

https://annales.sum.edu.pl/Serum-levels-of-VEGF-A-sVEGFR-2-and-galectin-3-do-not-correlate-with-clinical-stage,149208,0,2.html

Similar Items